Review Article

Biomarkers in Ovarian Cancer Screening

Paula Anastasia, RN, MN, AOCN

From Cedars-Sinai Medical Center, Los Angeles, California.

The author has no conflicts of interest to disclose.

Correspondence to: Paula Anastasia, RN, MN, AOCN®, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Amgeles, CA 90048. E-mail: AnastasiaP@cshs.org.


J Adv Pract Oncol 2010;1:97–105 | DOI: 10.6004/jadpro.2010.1.2.12 | © 2010 Harborside Press


  

ABSTRACT

There are no effective early-detection modalities for epithelial ovarian cancer (EOC), the fifth leading cause of cancer death in women. However, the 5-year survival rate for women diagnosed with stage I disease is 90%, demonstrating the need for improved early-detection methods. Biomarkers are used in conjunction with clinical assessment, for screening and detecting cancer occurrence, and for determining response and recurrence. Currently, two biomarkers (CA-125 and HE4) are used for monitoring and identification of recurrence of EOC; a third marker (OVA1) is used as the differential in a preoperative setting. In addition to serum markers, researchers are looking at an ovarian cancer symptom index, which may improve specificity to malignancy detection. Ultimately, the clinical benefit of a marker depends on its behavior preceding the months and years prior to symptoms, while the malignancy is developing. The best screening test will detect the early-stage and noninvasive cancers.


For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.